ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 140 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.08 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,521,501 | +41.2% | 286,535 | +153.3% | 0.00% | – |
Q2 2023 | $1,077,920 | -67.1% | 113,108 | -62.0% | 0.00% | -100.0% |
Q1 2023 | $3,278,231 | +604.7% | 298,021 | +848.1% | 0.00% | – |
Q4 2022 | $465,208 | -69.8% | 31,433 | -61.0% | 0.00% | – |
Q3 2022 | $1,539,000 | -65.7% | 80,515 | -61.7% | 0.00% | -100.0% |
Q2 2022 | $4,483,000 | +9.6% | 210,411 | -0.9% | 0.00% | 0.0% |
Q1 2022 | $4,091,000 | -29.5% | 212,400 | -24.1% | 0.00% | 0.0% |
Q4 2021 | $5,806,000 | -14.9% | 279,915 | -2.0% | 0.00% | 0.0% |
Q3 2021 | $6,826,000 | -46.4% | 285,732 | -38.7% | 0.00% | -66.7% |
Q2 2021 | $12,725,000 | -2.8% | 466,312 | +3.1% | 0.00% | 0.0% |
Q1 2021 | $13,089,000 | +248.0% | 452,456 | +238.4% | 0.00% | +200.0% |
Q4 2020 | $3,761,000 | +735.8% | 133,703 | +771.0% | 0.00% | – |
Q3 2020 | $450,000 | -55.0% | 15,350 | -53.6% | 0.00% | – |
Q2 2020 | $1,000,000 | -39.6% | 33,089 | -40.4% | 0.00% | -100.0% |
Q1 2020 | $1,656,000 | – | 55,565 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Frazier Life Sciences Management, L.P. | 8,434,232 | $162,443,000 | 13.84% |
Bain Capital Life Sciences Investors, LLC | 3,979,292 | $76,641,000 | 7.44% |
Pivotal bioVenture Partners Investment Advisor LLC | 569,041 | $10,960,000 | 5.19% |
Logos Global Management LP | 1,500,000 | $28,890,000 | 3.75% |
Omega Fund Management, LLC | 623,836 | $12,015,000 | 2.46% |
Orbimed Advisors | 6,073,850 | $116,982,000 | 1.90% |
MPM BioImpact LLC | 258,500 | $4,979,000 | 1.34% |
1492 Capital Management LLC | 75,192 | $1,448,000 | 0.77% |
SECTORAL ASSET MANAGEMENT INC | 219,136 | $4,221,000 | 0.75% |
EcoR1 Capital, LLC | 895,503 | $17,247,000 | 0.54% |